

Paul Tuite

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7857666/publications.pdf>

Version: 2024-02-01

56
papers

4,612
citations

201385

27
h-index

182168

51
g-index

60
all docs

60
docs citations

60
times ranked

5914
citing authors

#	ARTICLE	IF	CITATIONS
1	A Controlled Trial of Rasagiline in Early Parkinson Disease. Archives of Neurology, 2002, 59, 1937.	4.9	559
2	High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Annals of Neurology, 1997, 42, 292-299.	2.8	508
3	Adenosine A _{2A} receptor antagonist istradefylline (KW6002) reduces "off" time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002â€USâ€005). Annals of Neurology, 2008, 63, 295-302.	2.8	333
4	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543.	4.5	312
5	Proprioception and Motor Control in Parkinson's Disease. Journal of Motor Behavior, 2009, 41, 543-552.	0.5	248
6	Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Annals of Neurology, 2002, 51, 625-630.	2.8	212
7	Dysfunction of the basal ganglia, but not the cerebellum, impairs kinaesthesia. Brain, 2003, 126, 2312-2322.	3.7	212
8	Altered Diffusion in the Frontal Lobe in Parkinson Disease. American Journal of Neuroradiology, 2008, 29, 501-505.	1.2	177
9	N-acetylcysteine Boosts Brain and Blood Glutathione in Gaucher and Parkinson Diseases. Clinical Neuropharmacology, 2013, 36, 103-106.	0.2	165
10	Elevated Pontine and Putamenal GABA Levels in Mild-Moderate Parkinson Disease Detected by 7 Tesla Proton MRS. PLoS ONE, 2012, 7, e30918.	1.1	156
11	Progressive ataxia and palatal tremor (PAPT): Clinical and MRI assessment with review of palatal tremors. Brain, 2004, 127, 1252-1268.	3.7	134
12	Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics, 2013, 14, 11-22.	0.7	131
13	Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Movement Disorders, 2007, 22, 334-340.	2.2	128
14	Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Movement Disorders, 2018, 33, 282-288.	2.2	122
15	The evaluation and management of patients with neuroleptic malignant syndrome. Neurologic Clinics, 2004, 22, 389-411.	0.8	113
16	Interval timing and Parkinson's disease: heterogeneity in temporal performance. Experimental Brain Research, 2007, 184, 233-248.	0.7	108
17	Safety of the tau-directed monoclonal antibody BII092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurology, The, 2019, 18, 549-558.	4.9	108
18	The perception of passive motion in Parkinson's disease. Journal of Neurology, 2007, 254, 655-663.	1.8	104

#	ARTICLE	IF	CITATIONS
19	Identification of a Novel Risk Locus for Progressive Supranuclear Palsy by a Pooled Genomewide Scan of 500,288 Single-Nucleotide Polymorphisms. <i>American Journal of Human Genetics</i> , 2007, 80, 769-778.	2.6	68
20	T1 ρ and T2 ρ MRI in the evaluation of Parkinson's disease. <i>Journal of Neurology</i> , 2010, 257, 964-968.	1.8	64
21	Weight and body mass index in Parkinson's disease patients after deep brain stimulation surgery. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 247-252.	1.1	58
22	ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand. <i>Journal of Immunological Methods</i> , 2008, 336, 22-29.	0.6	53
23	The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. <i>Movement Disorders</i> , 2016, 31, 924-932.	2.2	48
24	Effects of yoga on oxidative stress, motor function, and non-motor symptoms in Parkinson's disease: a pilot randomized controlled trial. <i>Pilot and Feasibility Studies</i> , 2018, 4, 162.	0.5	48
25	Selective impairments in implicit learning in Parkinson's disease. <i>Brain Research</i> , 2007, 1137, 104-110.	1.1	46
26	Haptic Perception of Object Curvature in Parkinson's Disease. <i>PLoS ONE</i> , 2008, 3, e2625.	1.1	39
27	Clinical and Pathologic Evidence of Corticobasal Degeneration and Progressive Supranuclear Palsy in Familial Tauopathy. <i>Archives of Neurology</i> , 2005, 62, 1453.	4.9	29
28	Recent developments in the pharmacological treatment of Parkinson's disease. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1335-1352.	1.9	28
29	Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease—A Pilot Study. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 744-750.	1.0	25
30	The effect of dopamine replacement therapy on haptic sensitivity in Parkinson's disease. <i>Journal of Neurology</i> , 2010, 257, 1992-1998.	1.8	24
31	Depth perception in cerebellar and basal ganglia disease. <i>Experimental Brain Research</i> , 2006, 175, 165-176.	0.7	23
32	Magnetic resonance imaging as a potential biomarker for Parkinson's disease. <i>Translational Research</i> , 2016, 175, 4-16.	2.2	23
33	Motor phenotype classification in moderate to advanced PD in BioFIND study. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 178-183.	1.1	20
34	Idiopathic generalized myokymia (Isaacs' syndrome) with hand posturing resembling dystonia. <i>Movement Disorders</i> , 1996, 11, 448-449.	2.2	16
35	Gaze Control and Foot Kinematics During Stair Climbing: Characteristics Leading to Fall Risk in Progressive Supranuclear Palsy. <i>Physical Therapy</i> , 2008, 88, 240-250.	1.1	16
36	Brain Magnetic Resonance Imaging (MRI) as a Potential Biomarker for Parkinson's Disease (PD). <i>Brain Sciences</i> , 2017, 7, 68.	1.1	16

#	ARTICLE	IF	CITATIONS
37	Parkinsonism: A Review-of-Systems Approach to Diagnosis. <i>Seminars in Neurology</i> , 2007, 27, 113-122.	0.5	15
38	Magnetization transfer and adiabatic R1Ë-MRI in the brainstem of Parkinsonâ€™s disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 623-625.	1.1	14
39	Inferior Olive Response to Passive Tactile and Visual Stimulation with Variable Interstimulus Intervals. <i>Cerebellum</i> , 2010, 9, 598-602.	1.4	13
40	White matter measures correlate with essential tremor severityâ€™A pilot diffusion tensor imaging study. <i>Brain and Behavior</i> , 2018, 8, e01039.	1.0	12
41	Hatha yoga training improves standing balance but not gait in Parkinson's disease. <i>Sports Medicine and Health Science</i> , 2020, 2, 80-88.	0.7	12
42	Cerebral Vein Thrombosis due to Hereditary Antithrombin III Deficiency. <i>Canadian Journal of Neurological Sciences</i> , 1993, 20, 158-161.	0.3	11
43	Quantitative Assessment of Occipital Metabolic and Energetic Changes in Parkinsonâ€™s Patients, Using In Vivo 31P MRS-Based Metabolic Imaging at 7T. <i>Metabolites</i> , 2021, 11, 145.	1.3	11
44	McLeod syndrome: Five new pedigrees with novel mutations. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 293-299.	1.1	9
45	Association between vestibuloocular reflex suppression during smooth movements of the head and attention deficit in progressive supranuclear palsy. <i>Movement Disorders</i> , 2006, 21, 910-915.	2.2	7
46	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 138-145.	1.1	7
47	POEMS syndrome in a 24-year-old man associated with vitamin B12 deficiency and a solitary lytic bone lesion. , 1997, 20, 1454-1456.		6
48	Constraint-induced movement therapy in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 910-911.	2.2	6
49	Gaze-shift strategies during functional activity in progressive supranuclear palsy. <i>Experimental Brain Research</i> , 2007, 178, 351-362.	0.7	6
50	White matter microstructure in Parkinsonâ€™s disease with and without elevated rapid eye movement sleep muscle tone. <i>Brain Communications</i> , 2022, 4, fcac027.	1.5	3
51	Erratum to â€™Weight and body mass index in Parkinson's disease patients after deep brain stimulation surgeryâ€™. [<i>Parkinsonism and Related Disorders</i> 11 (2005) 247â€™252]. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 121.	1.1	2
52	Preliminary N-acetylcysteine results for LDN 6722 - Role of oxidative stress and inflammation in Gaucher disease type 1: Potential use of antioxidant anti-inflammatory medications. <i>Molecular Genetics and Metabolism</i> , 2019, 126, S82.	0.5	2
53	Magnetic resonance imaging (MRI) methods in Parkinson's disease. , 0, , 1-13.		1
54	Imaging iron in Parkinson's disease. , 0, , 14-25.		0

#	ARTICLE	IF	CITATIONS
55	Motor Parkinson's disease and structure. , 0, , 26-43.		0
56	MRI in clinical trials. , 0, , 264-270.		0